ArticleHeart views : the official journal of the Gulf Heart Association
A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination.
Article in Heart views : the official journal of the Gulf Heart Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 messenger RNA (mRNA) vaccine-related myocarditis, though rare, primarily affects young males and often presents its symptoms within the 1st week postvaccination. Aims and Objectives: To assess the long-term outcomes of individuals diagnosed with myocarditis following COVID-19 vaccination. Materials and Methods: We conducted a case series analysis involving 17 patients diagnosed with inflammatory myocarditis. Results: Symptoms in these patients typically appeared 24-96 h after receiving the COVID-19 mRNA vaccine. Fortunately, the prognosis for these patients is generally favorable, characterized by good short-term recovery and minimal long-term consequences. Follow-up cardiac magnetic resonance imaging (CMR) among our patients revealed alongside a preserved ejection fraction, the absence of fibrosis in 7 out of 13 (54%) patients with minimal residual fibrosis in 5 (38%) patients, whereas the remaining one patient demonstrated fibrosis consistent with hypertrophic cardiomyopathy. Conclusion: Despite the seemingly benign nature of COVID-19 mRNA vaccine-related myocarditis thus far, it is crucial to emphasize the necessity of prolonged clinical and CMR follow-up exceeding 1 year. Extended monitoring is essential to gain a deeper understanding of the true nature of this condition and its potential implications. This comprehensive approach will contribute significantly to ensuring the ongoing safety and efficacy of COVID-19 vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.